Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 11:41 AM ET


Company Overview of Quanterix Corporation

Company Overview

Quanterix Corporation develops and provides ultra-sensitive diagnostic platform for measuring individual proteins. The company offers Single Molecule Array technology that enables the detection and quantification of biomarkers in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more; assay kits; and consumables. Its products are used in life science research, oncology, neurology, inflammatory disease, and infectious disease applications. Quanterix Corporation was formerly known as Digital Genomics Inc. and changed its name to Quanterix Corporation in August 2007. The company was founded in 2007 and is based in Lexington, Massachusetts.

13 Hartwell Avenue

Suite B14201

Lexington, MA 02421

United States

Founded in 2007





Key Executives for Quanterix Corporation

Executive Chairman and Chief Executive Officer
President and Director
Co-Founder, Chairman of Scientific Advisory Board and Director
Age: 62
Chief Financial Officer and Vice President of Finance & Administration
Chief Technology Officer and Vice President of Research
Compensation as of Fiscal Year 2015.

Quanterix Corporation Key Developments

Quanterix Corporation Launches Next Generation Simoa 2.0 Ultrasensitive Immunoassay Platform

Quanterix Corporation announced the launch of Simoa 2.0, its next-generation ultrasensitive immunoassay platform. The Simoa 2.0 improvements will be available to all current Quanterix customers with a simple upgrade procedure and will be offered at no cost to ensure all users can benefit from the upgrades without any additional investment or interruption of their research. The upgrade includes numerous hardware and software advances and a comprehensive training program to ensure customers benefit from the many new features and capabilities. A number of beta customers around the world have already adopted Simoa 2.0 over the last few months and reported remarkable improvements in assay robustness, overall performace, reliability and ease of use.

Quanterix Corporation Seeks An IPO

Quanterix Corporation is planning to go public through initial public offering (IPO). Quanterix have begun conversations with investors on plotting an IPO. Kevin Hrusovsky, Chief Executive Officer of Quanterix said, "We’ll be doing that as part of our build out to become a public company. I would predict that we’ll be ready to do an IPO as early as early next year."

Quanterix Corporation Announces Commercial Availability of its Multiplex Panels and Homebrew Kits for Biomarker Discovery and Validation

Quanterix Corporation announced commercial availability of its multiplex panels, providing users with the ability to develop their own multiplex assays using the company’s ultra-sensitive Simoa technology. This allows users to achieve similar sensitivity with each marker in a multiplex panel as they would if they were to test individual assays. The company has also developed a convenient multiplex homebrew kit, allowing customers to use their own antibody pairs to develop custom multiplex Simoa panels, providing unlimited flexibility and significant cost savings. Researchers and clinicians want the ability to test for several different biomarkers on a small sample, making it possible to consider alternative, less invasive samples than the traditional blood test. The company's menu of Simoa assay kits has been growing rapidly and has now reached 30 assays, including markers for oncology, cardiology, neurology, infectious disease and inflammatory disease, all of which allow researchers to measure the associated biomarkers at levels that were impossible to measure until now. The first commercially available multiplex kits are 3-plex panels of cytokines, which are very useful for measuring inflammatory response across a wide range of conditions. These new panels are composed of individual cytokines that have been most popular with Simoa customers over the past year in singleplex format. The normal healthy range for many cytokines is close to the limit of detection of conventional immunoassay measurement techniques. Because of this, the sensitivity provided by Simoa allows researchers to measure both healthy and sick subjects with confidence, leading to a significant increase in demand for Simoa cytokine assays over the past year.

Similar Private Companies By Industry

Company Name Region
fqubed, Inc. United States
ChromBA, Inc. United States
MIgS LLC United States
Target Discovery, Inc. United States
CellExSys, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Quanterix Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at